Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | BRAF |
Variant | T599_V600insS |
Impact List | insertion |
Protein Effect | unknown |
Gene Variant Descriptions | BRAF T599_V600insS results in the insertion of a serine (S) in the protein kinase domain of the Braf protein between amino acids 599 and 600 (UniProt.org). T599_V600insS has not been characterized in the scientific literature and therefore, its effect on Braf protein function is unknown (PubMed, Sep 2024). |
Associated Drug Resistance | |
Category Variants Paths |
BRAF mutant BRAF T599_V600insS |
Transcript | NM_004333.6 |
gDNA | chr7:g.140753337_140753338insGCT |
cDNA | c.1797_1798insAGC |
Protein | p.T599_V600insS |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_004333.6 | chr7:g.140753337_140753338insGCT | c.1797_1798insAGC | p.T599_V600insS | RefSeq | GRCh38/hg38 |
NM_001378468.1 | chr7:g.140753337_140753338insGCT | c.1797_1798insAGC | p.T599_V600insS | RefSeq | GRCh38/hg38 |
NM_004333 | chr7:g.140753337_140753338insGCT | c.1797_1798insAGC | p.T599_V600insS | RefSeq | GRCh38/hg38 |
NM_001378474.1 | chr7:g.140753337_140753338insGCT | c.1797_1798insAGC | p.T599_V600insS | RefSeq | GRCh38/hg38 |
XM_005250045 | chr7:g.140753337_140753338insGCT | c.1797_1798insAGC | p.T599_V600insS | RefSeq | GRCh38/hg38 |
NM_001354609.1 | chr7:g.140753337_140753338insGCT | c.1797_1798insAGC | p.T599_V600insS | RefSeq | GRCh38/hg38 |
NM_004333.5 | chr7:g.140753337_140753338insGCT | c.1797_1798insAGC | p.T599_V600insS | RefSeq | GRCh38/hg38 |
NM_001354609.2 | chr7:g.140753337_140753338insGCT | c.1797_1798insAGC | p.T599_V600insS | RefSeq | GRCh38/hg38 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03843775 | Phase Ib/II | Binimetinib + Encorafenib | A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers | Completed | USA | 0 |